低剂量率近距离放疗治疗前列腺癌的长期肿瘤学与功能随访:瑞士前瞻性全国注册研究结果
该研究基于瑞士12中心前瞻性注册数据,评估低剂量率近距离放疗(LDR-BT)的长期肿瘤学、功能及毒性结局。中位随访37.1个月,Gleason评分≤3+4、初始PSA<10 ng/mL及D'Amico低危组与更好的生化无复发生存相关;功能结局在2–3年恢复至接近基线。
要点
- LDR-BT在长期随访中显示良好的肿瘤学控制与功能结局。
- Gleason评分≤3+4、初始PSA<10 ng/mL及低危组预示更优BRFS。
- 复发患者植入后6周D90显著更低,支持剂量与复发相关。
核心结论
- LDR-BT与良好的长期肿瘤学结局和功能结果相关,与其他研究一致。
研究设计与样本
- 前瞻性多中心队列研究,纳入2004年9月至2018年3月瑞士12个中心接受LDR-BT的患者。
- 数据库共1580例,1291例(81.7%)可评估治疗结局,随访≥3个月者纳入分析。
- 中位随访37.1个月(范围3.0–141.6个月),使用125I粒子,植入后6周基于欧洲放射肿瘤学会推荐进行剂量测定。
主要发现
- Gleason评分≤3+4者生化无复发生存(BRFS)更优(P=0.03,log-rank检验)。
- 初始PSA<10 ng/mL者BRFS更优(P<0.001)。
- D'Amico风险分组与BRFS显著相关(P<0.001),中高危 vs 低危的风险比为2.38。
- 复发患者植入后6周覆盖90%前列腺体积的辐射剂量(D90)显著更低。
- 功能结局在2–3年后恢复至接近基线水平。
关键数值与推荐
- 生化失败定义为PSA升高超过PSA最低值+2。
- 剂量测定在植入后6周依据欧洲放射肿瘤学会推荐进行。
临床怎么用
- 对于低危前列腺癌患者,LDR-BT可作为兼顾肿瘤控制与功能保留的治疗选择。
- 植入后6周D90较低者复发风险更高,应关注剂量质量。
局限性
- 随访丢失较多是本研究的主要局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the long-term oncological, functional and toxicity outcomes of low-dose-rate brachytherapy (LDR-BT) in relation to risk factors and radiation dose in a prospective multicentre cohort. PATIENTS AND METHODS: Data of patients from 12 Swiss centres undergoing LDR-BT from September 2004 to March 2018 were prospectively collected. Patients with a follow-up of ≥3 months were analysed. Functional and oncological outcomes were assessed at ~6 weeks, 6 and 12 months after implantation and annually thereafter. LDR-BT was performed with 125 I seeds. Dosimetry was done 6 weeks after implantation based on the European Society for Radiotherapy and Oncology recommendations. The Kaplan-Meier method was used for biochemical recurrence-free survival (BRFS). A prostate-specific antigen (PSA) rise above the PSA nadir + 2 was defined as biochemical failure. Functional outcomes were assessed by urodynamic measurement parameters and questionnaires. RESULTS: Of 1580 patients in the database, 1291 (81.7%) were evaluable for therapy outcome. The median (range) follow-up was 37.1 (3.0-141.6) months. Better BRFS was found for Gleason score ≤3+4 (P = 0.03, log-rank test) and initial PSA level of <10 ng/mL (P < 0.001). D'Amico Risk groups were significantly associated with BRFS (P < 0.001), with a hazard ratio of 2.38 for intermediate- and high-risk patients vs low-risk patients. The radiation dose covering 90% of the prostate volume (D90) after 6 weeks was significantly lower in patients with recurrence. Functional outcomes returned close to baseline levels after 2-3 years. A major limitation of these findings is a substantial loss to follow-up. CONCLUSION: Our results are in line with other studies showing that LDR-BT is associated with good oncological outcomes together with good functional results.
引用
- Viktorin-Baier P, Putora PM, Schmid HP, et al. Long-term oncological and functional follow-up in low-dose-rate brachytherapy for prostate cancer: results from the prospective nationwide Swiss registry. BJU Int. 2020. PMID: 31965694. doi:10.1111/bju.15003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。